UY31420A1 - Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina - Google Patents

Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina

Info

Publication number
UY31420A1
UY31420A1 UY31420A UY31420A UY31420A1 UY 31420 A1 UY31420 A1 UY 31420A1 UY 31420 A UY31420 A UY 31420A UY 31420 A UY31420 A UY 31420A UY 31420 A1 UY31420 A1 UY 31420A1
Authority
UY
Uruguay
Prior art keywords
arylindenopirimidins
adenosine
antagonists
receiver
arylindenopyrimidine
Prior art date
Application number
UY31420A
Other languages
English (en)
Inventor
Paul F Jackson
Brian C Shook
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31420A1 publication Critical patent/UY31420A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se refiere a una nueva arilindenopirimidina, A, y a sus usos terapéuticos y profilácticos. Los trastornos tratados o evitados incluyen la enfermedad de Parkinson.
UY31420A 2007-10-24 2008-10-24 Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina UY31420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98224707P 2007-10-24 2007-10-24

Publications (1)

Publication Number Publication Date
UY31420A1 true UY31420A1 (es) 2009-04-30

Family

ID=40091927

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31420A UY31420A1 (es) 2007-10-24 2008-10-24 Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina

Country Status (12)

Country Link
US (1) US8017614B2 (es)
EP (1) EP2217575A1 (es)
JP (1) JP2011500819A (es)
CN (1) CN101835759A (es)
AR (1) AR069009A1 (es)
AU (1) AU2008317034A1 (es)
CL (1) CL2008003131A1 (es)
PA (1) PA8801501A1 (es)
PE (1) PE20091344A1 (es)
TW (1) TW200934493A (es)
UY (1) UY31420A1 (es)
WO (1) WO2009055308A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105540A1 (en) * 2009-10-29 2011-05-05 Jackson Paul F 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST
WO2012031383A1 (zh) * 2010-09-06 2012-03-15 中国科学院广州生物医药与健康研究院 酰胺类化合物
WO2013156614A1 (en) 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
WO2005042500A1 (en) 2003-10-03 2005-05-12 Ortho-Mcneil Pharmaceutical, Inc. Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist

Also Published As

Publication number Publication date
AU2008317034A1 (en) 2009-04-30
CN101835759A (zh) 2010-09-15
JP2011500819A (ja) 2011-01-06
EP2217575A1 (en) 2010-08-18
TW200934493A (en) 2009-08-16
PE20091344A1 (es) 2009-09-24
WO2009055308A1 (en) 2009-04-30
CL2008003131A1 (es) 2010-02-19
US8017614B2 (en) 2011-09-13
PA8801501A1 (es) 2009-05-15
AR069009A1 (es) 2009-12-23
US20090111827A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
PA8548901A1 (es) Ligandos del receptor 5-ht y sus usos
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
CO6470876A2 (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak.
ECSP11011019A (es) Antagonistas del receptor de orexina de isonicotinamida
BRPI0614397A2 (pt) compostos de pirimidina como moduladores de receptor de serotonina
UY32583A (es) Composiciones y métodos para aumentar el crecimiento muscular
NO20080278L (no) Prodrugs av A2B-adenosinreseptorantagonister
HN2008001530A (es) Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
CO6321169A2 (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas de receptores de adenosina a2a
HN2006007774A (es) Imidazoles sustituidos con heterociclilamida
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
UY31421A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
CL2008001007A1 (es) Compuestos derivados de furo[2,3-b] piridina, moduladores del receptor canabinoide-1; y su uso para tratar psicosis, deficit de memoria, trastornos cognitivos, entre otras enfermedades.
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo
SV2009002893A (es) Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida ref. prd2560